Novartis Gains First-ever Approval for Infant Malaria Medicine
In a breakthrough for pediatric malaria treatment, Novartis has received approval from Swissmedic for Coartem® (artemether-lumefantrine) Baby, marking the first-ever
Read moreIn a breakthrough for pediatric malaria treatment, Novartis has received approval from Swissmedic for Coartem® (artemether-lumefantrine) Baby, marking the first-ever
Read moreGilead Sciences, Inc. (Nasdaq: GILD) has announced that the U.S. Food and Drug Administration (FDA) has approved Yeztugo® (lenacapavir) as
Read moreWe find the right DNA polymerase for you! myPols Biotec can advise you on finding the right polymerase for your
Read moreSeNostic is Revolutionising Neurodegenerative Disease Detection and Drug Discovery with Cutting-Edge Technology A SeNostic Company Presentation SeNostic aims to enhance
Read moreHarbour BioMed has entered into a global strategic collaboration with Otsuka Pharmaceutical Co., Ltd., granting Otsuka exclusive rights to develop,
Read moreSanofi has announced a definitive agreement to acquire Blueprint Medicines, a U.S.-based biopharmaceutical company focused on systemic mastocytosis (SM) and
Read moreStriatech, a leader in preclinical vision research devices and tools, has unveiled its New Non-Aversive Animal Platform for the OptoDrum
Read moreSanofi has announced a definitive agreement to acquire clinical-stage biotech firm Vigil Neuroscience, Inc., in a move to expand its
Read moreStriatech, a pioneer in non-invasive vision research technologies, will showcase its latest advancements at the FELASA 2025 Congress in Athens,
Read moreBioMarin Pharmaceutical Inc. has entered into a definitive agreement to acquire clinical-stage biotech Inozyme Pharma, Inc. for approximately $270 million
Read more